Pfizer on Thursday became the first research-based pharmaceutical company to agree a deal with the Clinton Foundation that substantially cuts the price of a medicine for patients in low-income countries.

The move, which signals fresh flexibility from the US company over drug pricing in developing countries, also undercuts Pfizer’s generic competitors.